Sixth Amendment to Revenue Interest Financing Agreement, dated as of March 17, 2025, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P
Exhibit 10.25
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT
This SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of March 17, 2025 (the “Sixth Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
WHEREAS, the Parties entered into that certain Revenue Interest Financing Agreement, dated as of January 9, 2023 (as amended by the First Amendment to the Revenue Interest Financing Agreement dated as of April 17, 2023, as amended by the Second Amendment to the Revenue Interest Finance Agreement dated as of June 28, 2023, as amended by the Third Amendment to the Revenue Interest Finance Agreement dated as of July 27, 2023, as amended by the Fourth Amendment to the Revenue Interest Finance Agreement dated as of January 3, 2024, and as amended by the Fifth Amendment to the Revenue Interest Finance Agreement dated as of September 11, 2024, the “Agreement”);
WHEREAS, pursuant to the Agreement, the Investor has funded the Initial Investment Amount in the amount of $32,500,000 and the Second Investment Amount has been funded by the Investor in the aggregate amount of $67,500,000 (funded in three separate Second Closings for $10,000,000, $25,000,000, and $32,500,000 respectively);
WHEREAS, the Company and the Investor have agreed that the Agreement be modified to provide (i) that the Second Investment Amount be increased to $167,500,000, and (ii) for changes to the Quarterly Fixed Payments due from the Company and to the definition of the IRR True-Up Payment Amount, subject to the terms and conditions herein; and
WHEREAS, the Parties desire to effect the agreements, acknowledgments and amendments to the Agreement contemplated by this Amendment.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
1
“”First Commercial Sale” means the first bona fide, arm’s length sale or transfer of the Existing Yutrepia Product to a Third Party in the United States following receipt of Regulatory Approval for the Existing Yutrepia Product. For clarity, Regulatory Approval for the Existing Yutrepia Product in the United States shall not be deemed to have been granted until both (i) final approval of New Drug Application No. 213005 has been granted by FDA and (ii) such final approval shall include approval for labeling for both (A) pulmonary arterial hypertension and (B) pulmonary hypertension associated with interstitial lung disease.”
““IRR True-Up Payment Amount” means, as of any time of determination, (i) the amount that the Investor would need to receive to yield an internal rate of return on the Investment Amount tendered prior to Fifth Amendment Effective Date (consisting of the Initial Investment Amount of $32,500,000 and the Second Investment Amounts of $10,000,000 and $25,000,000, respectively funded on July 27, 2023 and January 4, 2024) equal to eighteen percent (18%), calculated using the “XIRR function” in Microsoft® Excel® and determined after taking into account the Total Fixed Payments, the Total Included Product Payments, the Under Performance Payments, the Generic Product Payment and any payments under the Insurance Policy received by the Investor Representative and/or the Investor, if any, (ii) the amount that the Investor would need to receive to yield an internal rate of return on the Second Investment Amount of (x) $32,500,000, tendered by the Investor to the Company on or around the Fifth Amendment Effective Date, and (y) $25,000,000 tendered by the Investor to the Company on the Sixth Amendment Effective Date, in each case, equal to sixteen percent (16%), calculated using the “XIRR function” in Microsoft® Excel® and determined after taking into account the Total Fixed Payments, the Total Included Product Payments, the Under Performance Payments, the Generic Product Payment and any payments under the Insurance Policy received by the Investor Representative and/or the Investor, if any, (iii) the amount that the Investor would need to receive to yield an internal rate of return on the Second Investment Amount of $50,000,000 to be funded after the First Commercial Sale has occurred in accordance with Section 8.3, if such amount is tendered, equal to thirteen percent (13%), calculated using the “XIRR function” in Microsoft® Excel® and determined after taking into account the Total Fixed Payments, the Total Included Product Payments, the Under Performance Payments, the Generic Product Payment and any payments under the Insurance Policy received by the Investor Representative and/or the Investor, if any, and (iv) the amount that the Investor would need to receive to yield an internal rate of return on the Second Investment Amount of $25,000,000 to be funded if the Company Group has achieved aggregate Net Sales of One Hundred Million Dollars ($100,000,000) or more at any time on or prior to June 30, 2026 and the Company and the Investor agreed for such funds to be tendered by the Investor in accordance with Section 8.3, if such amount is tendered, equal to twelve percent (12%), calculated using the “XIRR function” in Microsoft® Excel® and determined after taking into account the Total Fixed Payments, the Total Included Product Payments, the Under Performance Payments, the Generic Product Payment and any payments under the Insurance Policy received by the Investor
2
Representative and/or the Investor, if any. For purposes of calculating the IRR True-Up Payment Amount, any voluntary prepayments made by the Company to the Investor Representative shall be applied first to the amounts owed by the Company to the Investor Representative and/or the Investor with respect to the Initial Investment Amount, followed by the amounts owed by the Company to the Investor Representative and/or the Investor with respect to each funded tranche of the Second Investment Amount in the order such tranches were funded, beginning with the portion of the Second Investment Amount funded on the first Second Closing Date. For reference, information on the XIRR function in Microsoft® Excel® is available at https://support.microsoft.com/en-us/office/xirr-function-de1242ec-6477-445b-b11b-a303ad9adc9d. An illustrative example of the calculation of the IRR True-Up Payment Amount is attached as Exhibit E hereto.”
““Second Closing Date” has the meaning set forth in Section 8.1(b). References to (x) the “Second Closing Date” contained in this Agreement or any other Transaction Document shall mean a reference to “the Second Closing Dates” or “the applicable Second Closing Date”, as the context may require, and (y) “the Second Closing” shall mean “a Second Closing”, “each Second Closing”, or “the applicable Second Closing”, as the context may require.”
“Sixth Amendment Effective Date” means March 17, 2025.”
“(b)up to an aggregate sum equal to One Hundred Sixty-Seven Million Five Hundred Thousand Dollars ($167,500,000) (the “Second Investment Amount”) at one or more Second Closing Dates, subject to the satisfaction of the conditions set forth in Section 8.3 and the performance of the obligations set forth in Section 8.6(c), in immediately available funds, by wire transfer to an account designated in writing by the Company to the Investor Representative prior to the applicable Second Closing Date.”
“(a) The Parties agree that for U.S. federal and applicable state and local income Tax purposes, (i) the Initial Investment Amount is intended to constitute a debt instrument that is subject to U.S. Treasury Regulations under Section 1.1275-4(b) governing contingent payment debt instruments and (ii) the Second Investment Amount is not a contingent payment debt instrument and is not subject to U.S. Treasury Regulations under Section 1.1275-4(b) governing contingent payment debt instruments, but instead is subject to the general rules governing debt instruments described in Section 1275(a)(1). Within ninety (90) days after the date of this Agreement (and, if applicable, each of the Second Closing Date, the Third Closing Date and the Fourth Closing Date), the Company will prepare and deliver to the Investor Representative a determination of the comparable yield and a projected payment schedule under Section 1.1275-4(b) (the “Comparable Yield”). Unless the Investor Representative objects to the Comparable Yield within fifteen (15) days after receipt thereof, the Comparable Yield shall become final and binding on the Parties. If the Investor Representative objects to the Comparable Yield within fifteen (15) days of receipt,
3
then the Parties shall cooperate in good faith to agree on a revised Comparable Yield within twenty (20) days of the Investor’s objection. The Parties intend that the provisions of the U.S. Treasury Regulation Section 1.1275-2(a)(1) would apply, subject to the exceptions in the U.S. Treasury Regulation Section 1.1275-2(a)(2), to treat any non-contingent payments on the debt instrument and the projected amount of any contingent payments as first, a payment of any accrued and any unpaid original issue discount at such time and second, a payment of principal (including for purposes of the rules applicable to “applicable high yield discount obligations”). The Parties agree not to take and to not cause or permit their Affiliates to take, any position that is inconsistent with the provisions of this Section 6.22(a) on any U.S. federal, state or local income Tax return or for any other U.S. federal, state or local income Tax purpose, unless required by Applicable Law or the good faith resolution of a Tax audit or other Tax proceeding.”
“(b)for each Closing related to the payment of all or any portion of the Second Investment Amount pursuant to Section 2.1(b) (each, a “Second Closing”), subject to the satisfaction of the conditions set forth Section 8.3 and Investor Representative’s receipt of a Second Closing Notice in accordance with Section 8.3, on the date that is fifteen (15) Business Days following the satisfaction of the conditions set forth in Section 8.3 and Section 8.6(c) or such other date as mutually agreed to by the Company and the Investor (each, a “Second Closing Date”);”
“Section 8.3“Conditions to Second Closing. The obligations of the Investor relating to the Second Closing shall be conditional upon (a) no Bankruptcy Event with respect to any member of the Company Group or no Special Termination Event, Change of Control, Default or Event of Default having occurred and be continuing (and the Investor Representative’s receipt of the certification from a Responsible Officer to that effect), and (b) Company providing written notice to Investor Representative of its election to receive the applicable portion of the Second Investment Amount (the “Second Closing Notice”). For clarity, the Investor shall (i) pay Twenty-Five Million Dollars ($25,000,000) of the Second Investment Amount on the Sixth Amendment Effective Date, (ii) have no obligation to pay the next Fifty Million Dollars ($50,000,000) of the Second Investment Amount until such time as the First Commercial Sale has occurred, and (iii) have no obligation to pay the final Twenty Five Million Dollars ($25,000,000) of the Second Investment Amount until such time as (x) the Company Group has achieved aggregate Net Sales (determined solely with respect to Yutrepia and not with respect to any other Included Product) in excess of One Hundred Million Dollars ($100,000,000) at any time on or prior to June 30, 2026, and (y) the Company and the Investor Representative mutually agree in writing for the Investor to fund such portion of the Second Investment Amount to the Company.”
“(iii) A certificate of a Responsible Officer of each Company Party certifying that (a) the representations and warranties set forth in ARTICLE IV or any other Transaction Document (other than the Fundamental Representations) are true and correct in all material respects on and as of the Second Closing Date (or, if made as of a specific date, as of such date); provided, that to the extent that any such representation or warranty is qualified by the term “material” or “Material Adverse Effect” such representation or warranty (as so written, including the term “material” or “Material Adverse Effect”) shall have been true and correct in all respects as of the date hereof and shall be
4
true and correct in all respects as of the Second Closing Date or such other date, as applicable, (b) that the Fundamental Representations are true and correct in all respects on and as of the Second Closing Date (or, if made as of a specific date, as of such date), subject to any additions that the Company may make to the Disclosure Schedule with respect to Section 4.10 and Section 4.12 (provided that any such additions to Section 4.12 of the Disclosure must be reasonably satisfactory to the Investor Representative (it being acknowledged that any addition that would not be reasonably expected to have a Material Adverse Effect shall be conclusively deemed satisfactory)) as of the Second Closing Date, (c) that each Company Party has complied in all material respects with its covenants, agreements and other obligations under this Agreement and the other Transaction Documents, and (d) that no court of competent jurisdiction has issued an injunction against a Company Party which would prohibit a Company Party from Commercializing the Existing Yutrepia Product in the United States for either or both of (A) pulmonary arterial hypertension and (B) pulmonary hypertension associated with interstitial lung disease.”
5
6
7
[Remainder of page intentionally left blank.]
8
IN WITNESS WHEREOF, the Parties have duly executed this Amendment as of the Sixth Amendment Effective Date.
| THE COMPANY: LIQUIDIA TECHNOLOGIES, INC. By: __/s/ Michael Kasta Name: Mike Kaseta Title: Chief Financial Officer |
[Signature Page to Sixth Amendment to the Revenue Interest Financing Agreement]
| INVESTOR REPRESENTATIVE: HEALTHCARE ROYALTY PARTNERS IV, L.P. By: HealthCare Royalty GP IV, LLC, its general partner By: ___/s/ Clarke Futch Name: Clarke B. Futch Title: Managing Partner |
[Signature Page to Sixth Amendment to the Revenue Interest Financing Agreement]
Acknowledged and Agreed,
LIQUIDIA CORPORATION
By: /s/ Michael Kaseta
Name: Mike Kaseta
Title: Chief Financial Officer
LIQUIDIA PAH, LLC
By: /s/ Michael Kaseta
Name: Mike Kaseta
Title: Chief Financial Officer
[Signature Page to Sixth Amendment to the Revenue Interest Financing Agreement]
EXHIBIT A
EXHIBIT C
EXAMPLE OF CALCULATION OF INCLUDED PRODUCT PAYMENT AMOUNT
N/A
FIXED PAYMENT SCHEDULE
[***]
EXHIBIT B
EXHIBIT E
ILLUSTRATIVE EXAMPLE OF IRR TRUE-UP PAYMENT
[***]